The development marks a significant transition for Innate Pharma as the company moves from mid-stage clinical development toward confirmatory testing and a potential regulatory filing for Sézary syndrome (SS), a rare and aggressive form of cutaneous T-cell lymphoma.

Innate said it plans to launch TELLOMAK-3, a confirmatory Phase 3 clinical trial evaluating lacutamab, subject to the closing of its strategic partnership with Sobi. The program is intended to support a planned accelerated approval filing based on data generated in the TELLOMAK Phase 2 program.

The partnership provides Innate with capital to fund this next stage. Sobi is expected to make a $75 million upfront payment when the transaction closes, while additional development milestones are tied to the program, including activities related to Sézary syndrome.

Innate expects the upfront payment to extend its projected cash runway through the third quarter of 2027, giving the company additional financial capacity to execute TELLOMAK-3 and prepare its regulatory submission.

The transaction remains subject to closing conditions, including antitrust clearance.

Lacutamab Moves Toward a Pivotal Test

Lacutamab is an investigational monoclonal antibody being developed for patients with cutaneous T-cell lymphoma. CTCL is a group of non-Hodgkin lymphomas that primarily affect the skin, with Sézary syndrome representing one of its more aggressive forms.

The planned TELLOMAK-3 study is important because Phase 3 trials generally provide the confirmatory evidence regulators use to evaluate whether a therapy's benefits outweigh its risks in a larger patient population.

Innate's strategy is somewhat unusual in that it is pursuing a potential accelerated approval pathway based on existing Phase 2 data while simultaneously preparing a confirmatory Phase 3 study.

The U.S. Food and Drug Administration's accelerated approval pathway can allow drugs for serious conditions addressing unmet medical needs to reach patients based on surrogate or intermediate clinical endpoints that are considered reasonably likely to predict clinical benefit. Confirmatory studies are then required to verify the expected benefit.

For Innate, successful execution of this strategy could shorten the path from clinical evidence to regulatory review while creating a larger evidentiary base through TELLOMAK-3.

The commercial opportunity is also shaped by the rarity of the disease. The National Cancer Institute estimates that cutaneous T-cell lymphomas account for a small proportion of non-Hodgkin lymphoma cases, reinforcing the importance of specialized therapies for patients with limited treatment options.

Sobi Partnership Changes the Development Equation

The planned Sobi collaboration gives Innate more financial flexibility at a point when clinical-stage biotechnology companies face significant capital requirements.

Late-stage clinical trials can require substantial investment, particularly when companies must simultaneously fund regulatory activities and other pipeline programs.

The $75 million upfront payment is therefore more than a balance-sheet event. It directly supports Innate's ability to advance lacutamab toward a pivotal study without relying entirely on near-term external financing.

Innate said it continues to explore other financing opportunities to support its strategic priorities.

The partnership also places lacutamab within a broader strategic framework. The company expects clinical developments involving IPH4502 and monalizumab to contribute to what management describes as three major developments for 2026.

That creates a portfolio approach rather than relying exclusively on a single oncology asset.

New Chief Medical Officer Brings Oncology Experience

Innate is also changing its clinical leadership as the company enters this later-stage development period.

Markus Jensen will become Chief Medical Officer and join the Executive Leadership Team on September 1, 2026, succeeding Sonia Quaratino.

Jensen joined Innate in 2024 as head of clinical pharmacology and has served as global clinical lead for several of the company's programs, including IPH4502. He brings more than 25 years of experience across clinical medicine, academic research and the pharmaceutical industry.

Before joining Innate, Jensen spent more than 16 years at Bayer, where his work included oncology and clinical development leadership.

That background could be particularly relevant as Innate transitions from exploratory and early-stage development toward regulatory execution.

The timing of the appointment also provides continuity. Jensen already has familiarity with Innate's pipeline and clinical programs, potentially reducing the disruption associated with a change in medical leadership during a critical development period.

Quaratino is departing the Chief Medical Officer role after overseeing clinical and regulatory progress including the development of lacutamab and completion of Phase 1 enrollment for IPH4502.

The Broader Oncology Pipeline

Innate's strategy extends beyond lacutamab.

The company expects IPH4502 and monalizumab to provide additional clinical catalysts. IPH4502 is part of Innate's antibody-drug conjugate pipeline, while monalizumab is an investigational immunotherapy targeting the NKG2A immune checkpoint.

The combination of a late-stage CTCL program with earlier oncology assets gives Innate multiple potential development milestones.

However, the risk profile remains typical of clinical-stage biotechnology. Advancing into Phase 3 does not guarantee regulatory approval, and accelerated approval strategies require confirmatory evidence demonstrating clinical benefit.

For investors and pharmaceutical partners, the key question will therefore be whether Innate can convert the existing Phase 2 evidence into a successful confirmatory program while continuing to advance its earlier pipeline.

What the Development Means for Medical Oncology

The Innate-Sobi partnership reflects a broader pharmaceutical industry trend: smaller biotechnology companies are increasingly using strategic collaborations to finance expensive late-stage development while retaining access to specialized research capabilities.

For patients with rare cancers such as Sézary syndrome, the development of targeted therapies can be particularly important because treatment options may be limited and disease progression can be difficult to manage.

If TELLOMAK-3 produces positive confirmatory data and the regulatory strategy succeeds, lacutamab could become an important addition to the therapeutic landscape for CTCL.

For now, the immediate milestones are clear: close the Sobi transaction, initiate TELLOMAK-3, prepare the planned regulatory filing and advance the company's other oncology programs.

Market Landscape

The biopharmaceutical industry continues to see partnerships become an important source of funding and development infrastructure for clinical-stage companies. Large pharmaceutical companies can provide capital, regulatory expertise, and commercialization capabilities, while biotech companies contribute specialized drug candidates and innovative research platforms.

Innate's agreement with Sobi follows that model, with the upfront payment specifically supporting a late-stage clinical program.

The oncology market remains particularly competitive, with companies investing heavily in targeted therapies, antibody-drug conjugates and immune-based approaches. For rare cancers, however, commercial success can depend less on enormous patient populations and more on demonstrating meaningful clinical benefit in diseases with substantial unmet need.

Strategic Outlook

Innate enters the next phase with three interconnected priorities: advance lacutamab into TELLOMAK-3, pursue a potential accelerated approval filing for Sézary syndrome and continue developing IPH4502 and monalizumab.

The Sobi partnership provides financial runway to execute those plans, while Jensen's appointment adds clinical-development continuity.

The major test will be execution. Phase 3 development and regulatory filing introduce a different level of operational complexity than earlier-stage trials. For Innate, 2026 could therefore establish whether its pipeline can transition from promising clinical assets into potentially commercial therapies.

Top Insights

• Innate Pharma plans TELLOMAK-3 Phase 3 testing for lacutamab, moving its CTCL program toward confirmatory evidence and a potential accelerated approval filing.
• Sobi's planned $75 million upfront payment is expected to extend Innate's cash runway through Q3 2027, supporting late-stage clinical execution.
• Markus Jensen becomes Chief Medical Officer in September, bringing more than 25 years of clinical and pharmaceutical experience to Innate's next development phase.
• The company is balancing lacutamab's late-stage development with upcoming milestones for IPH4502 and monalizumab across its oncology pipeline.
• Success will depend on TELLOMAK-3 execution, regulatory outcomes and Innate's ability to advance multiple clinical programs without excessive financing pressure.

Get in touch with our MarTech Experts